CN101861331B - Hypoallergenic variants of the major allergen from betula verrucosa pollen - Google Patents
Hypoallergenic variants of the major allergen from betula verrucosa pollen Download PDFInfo
- Publication number
- CN101861331B CN101861331B CN200880116680.6A CN200880116680A CN101861331B CN 101861331 B CN101861331 B CN 101861331B CN 200880116680 A CN200880116680 A CN 200880116680A CN 101861331 B CN101861331 B CN 101861331B
- Authority
- CN
- China
- Prior art keywords
- gly
- seq
- bet
- ser
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013566 allergen Substances 0.000 title claims abstract description 25
- 241000219430 Betula pendula Species 0.000 title claims abstract description 14
- 230000000774 hypoallergenic effect Effects 0.000 title abstract 2
- 235000009109 Betula pendula Nutrition 0.000 title description 12
- 208000026935 allergic disease Diseases 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 230000001225 therapeutic effect Effects 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 241000196324 Embryophyta Species 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000009257 reactivity Effects 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 8
- 230000002009 allergenic effect Effects 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 102000003916 Arrestin Human genes 0.000 description 28
- 108090000328 Arrestin Proteins 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 25
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 15
- CQZDZKRHFWJXDF-WDSKDSINSA-N Gly-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CN CQZDZKRHFWJXDF-WDSKDSINSA-N 0.000 description 12
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 238000011534 incubation Methods 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000008034 disappearance Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- MVBWLRJESQOQTM-ACZMJKKPSA-N Ala-Gln-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O MVBWLRJESQOQTM-ACZMJKKPSA-N 0.000 description 6
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 6
- LNNSWWRRYJLGNI-NAKRPEOUSA-N Ala-Ile-Val Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O LNNSWWRRYJLGNI-NAKRPEOUSA-N 0.000 description 6
- GWIJZUVQVDJHDI-AVGNSLFASA-N Asp-Phe-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O GWIJZUVQVDJHDI-AVGNSLFASA-N 0.000 description 6
- WDQXKVCQXRNOSI-GHCJXIJMSA-N Cys-Asp-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WDQXKVCQXRNOSI-GHCJXIJMSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- OIIIRRTWYLCQNW-ACZMJKKPSA-N Gln-Cys-Asn Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O OIIIRRTWYLCQNW-ACZMJKKPSA-N 0.000 description 6
- XKPACHRGOWQHFH-IRIUXVKKSA-N Gln-Thr-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XKPACHRGOWQHFH-IRIUXVKKSA-N 0.000 description 6
- KKCUFHUTMKQQCF-SRVKXCTJSA-N Glu-Arg-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O KKCUFHUTMKQQCF-SRVKXCTJSA-N 0.000 description 6
- CQAHWYDHKUWYIX-YUMQZZPRSA-N Glu-Pro-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O CQAHWYDHKUWYIX-YUMQZZPRSA-N 0.000 description 6
- NNQDRRUXFJYCCJ-NHCYSSNCSA-N Glu-Pro-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O NNQDRRUXFJYCCJ-NHCYSSNCSA-N 0.000 description 6
- QGZSAHIZRQHCEQ-QWRGUYRKSA-N Gly-Asp-Tyr Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QGZSAHIZRQHCEQ-QWRGUYRKSA-N 0.000 description 6
- VAXIVIPMCTYSHI-YUMQZZPRSA-N Gly-His-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN VAXIVIPMCTYSHI-YUMQZZPRSA-N 0.000 description 6
- ITZOBNKQDZEOCE-NHCYSSNCSA-N Gly-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CN ITZOBNKQDZEOCE-NHCYSSNCSA-N 0.000 description 6
- SCWYHUQOOFRVHP-MBLNEYKQSA-N Gly-Ile-Thr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SCWYHUQOOFRVHP-MBLNEYKQSA-N 0.000 description 6
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 6
- VYUXYMRNGALHEA-DLOVCJGASA-N His-Leu-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O VYUXYMRNGALHEA-DLOVCJGASA-N 0.000 description 6
- AIPUZFXMXAHZKY-QWRGUYRKSA-N His-Leu-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AIPUZFXMXAHZKY-QWRGUYRKSA-N 0.000 description 6
- MJUUWJJEUOBDGW-IHRRRGAJSA-N His-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 MJUUWJJEUOBDGW-IHRRRGAJSA-N 0.000 description 6
- UDLAWRKOVFDKFL-PEFMBERDSA-N Ile-Asp-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N UDLAWRKOVFDKFL-PEFMBERDSA-N 0.000 description 6
- CYHJCEKUMCNDFG-LAEOZQHASA-N Ile-Gln-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N CYHJCEKUMCNDFG-LAEOZQHASA-N 0.000 description 6
- ZUPJCJINYQISSN-XUXIUFHCSA-N Ile-Met-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N ZUPJCJINYQISSN-XUXIUFHCSA-N 0.000 description 6
- YBKKLDBBPFIXBQ-MBLNEYKQSA-N Ile-Thr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)O)N YBKKLDBBPFIXBQ-MBLNEYKQSA-N 0.000 description 6
- RMJWFINHACYKJI-SIUGBPQLSA-N Ile-Tyr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RMJWFINHACYKJI-SIUGBPQLSA-N 0.000 description 6
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 6
- PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 6
- MNGBICITWAPGAS-BPUTZDHNSA-N Met-Ser-Trp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O MNGBICITWAPGAS-BPUTZDHNSA-N 0.000 description 6
- IQJMEDDVOGMTKT-SRVKXCTJSA-N Met-Val-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IQJMEDDVOGMTKT-SRVKXCTJSA-N 0.000 description 6
- LQZZPNDMYNZPFT-KKUMJFAQSA-N Pro-Gln-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LQZZPNDMYNZPFT-KKUMJFAQSA-N 0.000 description 6
- RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 description 6
- LSHUNRICNSEEAN-BPUTZDHNSA-N Ser-Val-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CO)N LSHUNRICNSEEAN-BPUTZDHNSA-N 0.000 description 6
- QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 6
- MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 6
- KHUVIWRRFMPVHD-JYJNAYRXSA-N Tyr-Met-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O KHUVIWRRFMPVHD-JYJNAYRXSA-N 0.000 description 6
- VLOYGOZDPGYWFO-LAEOZQHASA-N Val-Asp-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VLOYGOZDPGYWFO-LAEOZQHASA-N 0.000 description 6
- KDKLLPMFFGYQJD-CYDGBPFRSA-N Val-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N KDKLLPMFFGYQJD-CYDGBPFRSA-N 0.000 description 6
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 6
- 108010087924 alanylproline Proteins 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 6
- 108010047857 aspartylglycine Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000013024 dilution buffer Substances 0.000 description 6
- 108010078144 glutaminyl-glycine Proteins 0.000 description 6
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 108010003700 lysyl aspartic acid Proteins 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 108010061238 threonyl-glycine Proteins 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000018185 Betula X alpestris Nutrition 0.000 description 4
- 235000018212 Betula X uliginosa Nutrition 0.000 description 4
- 244000241257 Cucumis melo Species 0.000 description 4
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 4
- SVSQSPICRKBMSZ-SRVKXCTJSA-N Lys-Pro-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O SVSQSPICRKBMSZ-SRVKXCTJSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 235000009847 Cucumis melo var cantalupensis Nutrition 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- GDOZQTNZPCUARW-YFKPBYRVSA-N Gly-Gly-Glu Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O GDOZQTNZPCUARW-YFKPBYRVSA-N 0.000 description 3
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 206010048908 Seasonal allergy Diseases 0.000 description 3
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 108010064235 lysylglycine Proteins 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229960004906 thiomersal Drugs 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- PEEYDECOOVQKRZ-DLOVCJGASA-N Ala-Ser-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PEEYDECOOVQKRZ-DLOVCJGASA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000219427 Fagales Species 0.000 description 2
- 102000002151 Microfilament Proteins Human genes 0.000 description 2
- 108010040897 Microfilament Proteins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- LKJCABTUFGTPPY-HJGDQZAQSA-N Thr-Pro-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O LKJCABTUFGTPPY-HJGDQZAQSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000726768 Carpinus Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 240000007582 Corylus avellana Species 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 235000009842 Cucumis melo Nutrition 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- SQXZLVXQXWILKW-KKUMJFAQSA-N Lys-Ser-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQXZLVXQXWILKW-KKUMJFAQSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Beans For Foods Or Fodder (AREA)
Abstract
The invention provides hypoallergenic variants of Bet v 2 major allergen from Betula verrucosa plant pollen and the use thereof for the preventive or therapeutic treatment of allergic diseases.
Description
The invention provides the low allergenicity sequence variants of Bet v 2 protein, its nucleic acid molecule of encoding, the pharmaceutical composition that comprises it and they purposes in the allergic disease that prevention and treatment are caused by the plant pollen from betula pendula (Betulaverrucosa) species.
Background technology
Transformation reactions is caused extremely by function of immune system, and described immunity system is by producing the harmless proteins react containing in IgE-antibody-like and pollen, mite, epithelium and some food.
Nearest data show in western countries to surpass 10% population and suffer from this disease, and its symptom can worsen in time, for example cause asthma or to other allergen sensitization, cause thus and select suitable methods for the treatment of more difficult.
Different from pharmacological treatments, the immunotherapy that specifically desensitizes (SIT) is unique cause of disease therapy of allergic disease, can successfully change the characteristic immune parameter of this class disease.
Desensitization immunotherapy comprise use increase dosage available from the standard extract (vaccine) (1) that causes the material of disease.Like this, patient progressively reduces a para-immunity tolerance of this material, and allergic symptoms disappears subsequently.
But, in fact cause that the risk (2) of serious side effects limits the application of specific desensitization immunotherapy in treatment allergic disease, although the vaccine that uses slowly-releasing vaccine or use non-injecting pathway to use significantly reduces this risk.
Most of attention has concentrated on effective, the safe vaccine of exploitation in recent years, especially comprises the vaccine (3) of the recombinant protein (can advantageously affect the nature process of disease and do not cause the low allergenicity variant of undesirable side effect) of mutagenic treatment.
If IgG antibody is specific for sensitization allergen, one of favorable factor of SIT is induction.This class (protection) antibody can suppress antigen-IgE combination, particularly suppresses IgE and is combined with Bet v 2 antigens, changes the three-dimensional conformation (4,5) of this molecule.Comprise the exploitation with the vaccine that does not change immunogenic low allergenicity recombinant protein and will improve the treatment of allergic disease.
The pollen that is called the plant (birch, alder, hazel, Oak Tree, hornbeam) of Fagales (Fagales) on taxonomy is one of Temperate Region in China main reason of causing rhinallergosis and asthma.Two kinds of main allergens of birch pollen, Bet v 1 (being kept at the cDNA of GenBank with accession number X15877) and Bet v 2 (accession number M65179), be that molecular weight is respectively 17 and the protein (6,7) of 14kD.Bet v2 belongs to arrestin family, its relate to regulate eukaryotic cell cytoskeleton all in cytoplasmic protein matter.They and at least two kinds of cells (greatly) interaction of molecules, this at least two kinds of cells (greatly) molecule is phosphatidylinositols-4,5-bisphosphate, thereby stop C-γ Phospholipid hydrolase (phospholypase) to the hydrolysis of this lipid acid (8), and Actin muscle, regulate and control its polymerization (9).They participate in regulating microfilament precursor the high expression level hint of arrestin in pollen ripe and that sprout, and this microfilament precursor participates in germination process (10).Arrestin is considered to from the allergen in multiple arbor and herbal pollen, with the allergen in various fruits and vegetables, therefore cast aside the fact that arrestin is only found in 20% pair of pollen allergic (allergy) patient, they are defined as " general-allergen (pan-allergens) " (11,12).
High sequence homology (higher than 60%) in the plant arrestin in the multiple source of major part causes crossed sensitization, not only between from corresponding plants (13) and the pollen of uncorrelated plant (14), also at pollen and vegetable food product (aliment, 15) between, or between pollen and rubber (latex) (16).Homology between plant arrestin and Mammals arrestin is lower, although proved that they can and demonstrate interchangeability (17,18,19) in conjunction with the Actin muscle from different plant species.Explanation is that all arrestin have similar three-dimensional structure, as used (20,21,22) as shown in X-radiocrystallography.
Many immune equivalents that studies confirm that arrestin.In fact, having shown can be in conjunction with the arrestin of different sources from the patient's of the pollen sensitization to definite IgE, in conjunction with the IgE of arrestin, can mutually suppress (16).
High cross reactivity between different pollen makes independent arrestin can be used for allergic effect reaction diagnosis, and restructuring Bet v 2 is typically used as the allergen (23,24) of selecting arrestin specific IgE to measure.
There is the research of many measure arrestin IgE epi-position.
According to the contemporaneously following research (26) carried out of identical group, Vrtala (1996) is at Phe44 and Gln47 mutagenesis Bet v 2, they are become to Tyr44, Glu47 and Asn47, in described research, identified the linear epitope of monoclonal antibody 4A6 identification.Use the epitope mapping of synthetic dodecapeptide (crossing over the whole aminoacid sequence of Bet v2) to this antibody recognition.More effectively the polypeptide in conjunction with this antibody contains the region between amino acid 38-49 and 40-51.In the combination of IgG-peptide, the importance of Gln47 residue can not be identified the arrestin from tobacco (Nicotiana tabacum) and thimothy grass (Phleum pratense) by following evidence prove: 4A6, and its sequence shows that L-glutamic acid is positioned at the Gln47 of Bet v 2.Different from Gln47 → Glu47 sudden change, the change from Phe44 to Tyr44 or the change from GIn47 to Asn47 do not affect the combination of antibody.As shown in the immune marking and ELISA test (25), the mutagenesis identical to restructuring Bet v 2 application (Gln47 is to Glu, or Asn and Phe44 are to Tyr44) can not reduce the combination between arrestin and IgE.
In disclosed research (22) subsequently in 1997, by the random fragment of clone birch arrestin cDNA, identified main IgE epi-position, the expression library that this cDNA uses by oneself the allergic patients serum of arrestin is analyzed.Prove more responding property of three regions, corresponding to the region that is positioned at N-terminal α spiral (aa 1-30).The region of the α spiral of carboxyl terminal (aa 106-132), and the region of the fragment that comprises residue 30-50.
In research (23) subsequently, the comparison between the theoretical construct model of the arrestin to the research of IgE epi-position based on from different plants and birch or rubber arrestin crystal.Predicted 11 possible conformational epitopes (comprising adjacent amino acid region), wherein at least 20% is exposed to surface.Aminoacid sequence and conformation model relatively obtain two class epi-positions: species specificity epi-position (being characterized by high variability) and high conservative epi-position, the latter more may relate to the cross reaction between different plant arrestin.The result of aminoacid sequence comparison reflection Fedorov research (22), proves at arrestin N-end and has two possible linear epitopes, have three possible linear epitopes, and all the other two is held between residue 30-80 at arrestin C-.In the plant arrestin that all these regions are evaluated and tested in this research, are all high conservatives.The analysis of the 3D model of the prediction of possible conformational epitope based on rubber arrestin Hev b8.This analytical proof be selected from table centrical 12 outstanding residues.Although all possible epi-position is all imaginations, they comprise linear order and conservative or variable residue.The test of the specific IgE-binding ability of the epi-position that report confirmation is not studied in this research.
More recent publication relates to the evaluation (27) of muskmelon (Cucumis melo) arrestin IgE epi-position.The IgE of peptide of whole aminoacid sequence that crosses over this protein by mensuration is reactive, two linear epitopes have been identified, wherein E1 is identified strongly to the allergic patients serum of muskmelon, comprises residue 66-75 and 81-93, and E2 is comprised of amino acid 95-99 and 122-131.Two other epi-position is replied sign by weak IgE, i.e. E3 (residue 2-10) and E4 (35-45).The overlapping expression of the epi-position E1 of corresponding muskmelon arrestin 3D model and the peptide of E2 has two region: E1 and the E2 of the electrostatic property of good definition, and it is relevant with electronegativity protein domain with positive polarity respectively.
Data representation IgE arrestin epi-position from document is positioned at molecular moiety wherein, but does not point out to relate to the amino acid of IgE combination.
Summary of the invention
Having now found that by the one or more amino-acid residues that replace or lack in Bet v 2 allergen sequences makes this allergen reduce the reactivity of IgE antibody.
First aspect, the invention provides low allergenicity protein, and it is the allergenic sequence variants of Bet v 2, and it is characterized in that:
1) compare with wild-type Bet v 2 allergens (SEQ ID NO:1), the reactivity of IgE is reduced;
2) aminoacid sequence is:
A) identical with SEQ ID NO:1 at least 90%, preferably at least 93% is identical, further preferentially at least 97% identical;
B) show that with the sequence alignment of SEQ ID NO:1 SEQ ID NO:1 is corresponding to (matching) Ser
39, Lys
45, Lys
88or Lys
89ser or Lys residue place there is at least one replacement or disappearance.
In preferred embodiments, the allergenic variant of Bet v 2 of the present invention shown in position there is a plurality of replacements or the disappearance in 1-3, wherein produce single, double or three replace and/or disappearance variant.Although can there is replacement and the disappearance of different aminoacids residue in Bet v 2 molecules simultaneously, preferably indicating site by the monosubstituted acquisition variant of one or more residues, particularly this type of residue is by the variant of neutrality, polarity or acidic amino acid displacement, described neutrality, polarity or acidic amino acid are selected from Ala, Thr, Gly, Pro, Leu, Ile, Ser, Phe, Glu, Asp, are more preferably selected from Ala, Thr, Ser, Gly, Glu, Asp.
The example of variant of the present invention is shown in SEQ ID NO:2 (1 residue replaces), SEQ ID NO:3 (1 residue replaces), SEQ ID NO:4 (2 residues replace), SEQ ID NO:5 (3 residues replace) and SEQ ID NO:6 (3 residues replace).
With respect to wild type counterparts (counterpart), Bet v of the present invention 2 allergens replace and/or disappearance variant shows the reactivity with betula pendula pollen-allergy patients serum's IgE, it reduces at least 10%, preferably at least 50%, more preferably at least 90%, wherein IgE reactivity detects by for example ELISA method for measuring.
IgE reactivity from the protein s EQ ID NO:2-6 in allergy patients serum storehouse is measured and is detected (Fig. 1) by ELISA.With respect to wild-type Bet v 2 allergens (SEQ ID NO:1), when (SEQID NO:2), (SEQ ID NO:3), (SEQ ID NO:4) and (SEQ ID NO:5 and 6) protein are when hatching from birch pollen allergy patient's Serum Bank, observe reactive average 92% (SEQ IDNO:2), 13% (SEQ ID NO:3), 97% (SEQ ID NO:4) and 93% (the SEQ ID NO:5 and 6) of reducing of IgE.
These results confirm by REAST inhibition test, and this test can be evaluated and tested the reactivity from the homology epi-position of different proteins.When there is 1.45ng inhibition, when serum pretreated with identical protein, wild-type Bet v 2 (SEQ ID NO:1) suppresses with the combination 82.6% from the IgE in allergy patients serum storehouse, when serum is used variant SEQ ID NO:2 and SEQ ID NO:3 preincubation, it is respectively 40.4% and 71% inhibition, and when serum uses respectively two replacement variants (SEQ IDNO:4) and three of same amount to replace variant (SEQ ID NO:5 and SEQ ID NO:6) preincubation, the inhibition of observing is only 13.4%, 4% and 8.8% (Fig. 2).
These results clearly show that the amino acid of the 39th, 45,88,89 of SEQ ID NO:1 participates in IgE to the allergenic identification of Bet v 2.
In addition, Balb/c mouse immune inoculation test proof wild-type Bet v 2 allergens and low allergenicity protein s EQ ID NO:5 (being selected from as exemplary sudden change allergen) all can induce IgG-specific immune response (Fig. 3).Anti-SEQ ID NO:5 antibody can be identified wild-type-counterpart SEQ IDNO:1 (Fig. 4), proves that the replacement of the 45th, 88,89 Lys-residues does not cause the great change of molecular immune originality, and changes its IgG epi-position.On the contrary, the antibody existing in the mice serum of uncorrelated antigen immune can not be identified wild-type Bet v 2 and SEQ ID NO:5.
On the other hand, the invention provides the corresponding immune-active peptides of Bet v 2 fragment, described immune-active peptides comprises at least one above-mentioned replacement and/or disappearance.Described peptide preferably contains 15-35 amino-acid residue, more preferably 15-20 amino-acid residue.Term used herein " immune-active peptides " means to cause the peptide of the immunne response that does not rely on IgE.
Use method known to those skilled in the art and technology, by mutagenesis wild-type Bet v 2cDNA sequence (SEQ ID NO:7), can easily prepare replacement of the present invention and/or disappearance variant.
Single, double and the three cDNA sequences that replace variant shown in coding SEQ ID NO:2-6 are reported in SEQ ID NO:8-12.
On the other hand, the invention provides the nucleic acid molecule of coding low allergenicity Bet v disclosed herein 2 variants, derived from its peptide, the expression vector that comprises this molecule, in wherein said molecule and eukaryotic cell or prokaryotic cell prokaryocyte, control the functional connection of genetic elements (for example transcripting promoter, enhanser, signal and leader sequence, or other sequences that relate in transcriptional control) of its expression.The example of carrier comprises plasmid, virus and phage, yet in genetic engineering, normally used any other carrier also can be used.
The present invention also comprises protokaryon or the eukaryotic host cell with carrier conversion of the present invention or transfection.Prokaryotic cell prokaryocyte is intestinal bacteria (Escherichia coli) or Bacillus subtilus (Bacillus subtilis) for example, or eukaryotic cell for example yeast saccharomyces cerevisiae (Saccharomyces cerevisiae) be typically used as clone or cDNA expression vector.
In addition, low allergenicity variant of the present invention can be used as fusion rotein preparation.
Because the IgE that they reduce is reactive, Bet v 2 variants of the present invention can be advantageously used in the preparation of pharmaceutical composition (for example tablet), and described pharmaceutical composition is for preventing or treat the allergy individuality of betula pendula pollen.
Therefore another aspect of the present invention is pharmaceutical composition, low allergenicity Bet v provided herein 2 variants that it comprises significant quantity, other allergens of the optional and betula pendula of this variant, and/or pharmaceutical acceptable carrier and excipient composition.In preferred embodiments, pharmaceutical composition is used for preventing or treating with vaccine form the allergic disease that comprises bronchial asthma, rhinallergosis, allergic dermatitis and allergic conjunctivitis.The theory of immunization and operation are (28,29) well known by persons skilled in the art.
The following example is further illustrated the present invention.Unless pointed out separately, in embodiment, method therefor is described in Sambrook, Fritsch ET Maniatis " Molecular cloning.A laboratorymanual " second edition, and 1-2-3 volume, CSH Lab publishes, and 1989.
Accompanying drawing summary
Fig. 1: the reactivity of elisa assay IgE and Bet v 2 allergens and Bet v 2 low allergenicity variants;
The inhibition that Fig. 2: IgE is combined with Betv 2 allergens;
Fig. 3: the replying of sudden change IgE and each immunogenic protein;
Fig. 4: the IgG in the mouse of SEQ ID NO:5 immunity replys.
The site-specific mutagenesis of embodiment 1-Bet v 2 allergen code cDNAs
The site-specific mutagenesis of Bet v 2 allergen code cDNAs (SEQ ID NO:7), by the cDNA clone in prokaryotic vector (pBluescript, GenBank accession number X52327), is then that pcr amplification carries out.The oligonucleotide (table) that is used as primer in PCR reaction has suitable base and replaces.For each mutagenesis, use the complementary oligonucleotide (30) that is attached to DNA chain respective regions.After amplification, the unaltered original template of enzymatic digestion degradation selectivity of restriction enzyme DpnI catalysis.Then with the molecule of mutagenesis, transform Bacillus coli cells.According to mulberry lattice (method), the clone available from single bacteria bacterium colony is checked order, to determine base modification correct in cDNA and not have non-specific sudden change.
Table. in site-specific mutagenesis, be used as the oligonucleotide sequence of primer.
The base of sudden change is black matrix.
Oligonucleotide | Sequence |
Bet v2 S39 | ggg ccc aga gcg ctt cct tcc cac ag |
Bet v2 K45 | cct tcc cac agt tta cgc ctc agg aaa tc |
Bet v2 K88-89 | gtc atc cgt gga ggg gag gga tct gga g |
Embodiment 2-prepares Bet v 2 albumen and variant thereof
According to standard scheme (31,32), in intestinal bacteria, clone and express (SEQ ID NO:8-12) Bet v 2cDNA of wild-type (SEQ ID NO.7) and mutagenesis.Cell centrifugation is collected, and is resuspended in PBS1X (6.46mM NaH
2pO
4, 1.47mM KH
2pO
4, 136.89mM NaCl) in and ultrasonic degradation.Centrifugation recombinant protein.The precipitation that contains insoluble protein aggregate is resuspended in PBS 1X, 6M urea (sex change damping fluid) and at 4 ℃, stirs 60 minutes.Recombinant protein centrifugation from insoluble residue of dissolving, with PBS 1X dialysis, the filter that filters 1 μ M is also used agarose column (Sigma, Milan, the Italy) affinitive layer purification of poly--proline(Pro) derivatize by use.With after PBS 1X, the washing of 2M urea, with PBS 1X, 8M urea wash-out recombinant protein, and 4 ℃ of dialysis carry out refolding for 16 hours in PBS 1X solution.
The sign of embodiment 3-allergy experimenter serum
Serum is collected from having has the clinical patient history of seasonal allergy to betula pendula pollen, and has the Bet v original RAST 3+ of 2 allergic effect and the atopic individuality of 4+, then concentrates these serum and uses with this form.Serum Bank from anallergic patient is used as negative control.
The reactive elisa assay of embodiment 4-Bet v 2 variants to IgE in Serum Bank
In 50mM carbonate/bicarbonate damping fluid (pH 9.6) the wild-type allergen of same amount and mutation variants (1 μ g) at 4 ℃ incubation 16 hours to be adsorbed onto on the hole of polystyrene for elisa assay (polystirene) plate.This is the washing soln (phosphate buffered saline buffer that 60mM contains 0.05%Tween-20 for hole, pH 6.5) washing, and seal with diluting soln (25% lowlenthal serum in 150mM phosphate buffered saline buffer, 1mM EDTA, 0.05%Tween 20,0.01% thiomersal(ate), pH 7.4).The aliquot sample of 70 μ l human serum RAST 3+ and 4+ storehouse (in dilution buffer liquid) is added to each sample, and in 25 ℃ of incubations 2 hours.Wash after three times, add peroxidase conjugated anti-human-IgE serum (in dilution buffer liquid 1: 1500), then 25 ℃ of incubations are 1.5 hours.After washing three times, add 100 μ l TMB reagent (BioFX Laboratories, Owings Mills, MD) and within 15 minutes, carry out colorimetric reaction at 25 ℃ of incubations.Add 100 μ l 1N HCl termination reactions and use microplate reader (microplate reader spectrophotometer) at 450nm place reading.
Embodiment 5-REAST suppresses to measure.The combination of the IgE comprising in Bet v 2 variants inhibition biotinylation Bet v 2 and Serum Bank
Be diluted at 1: 3 in dilution buffer liquid (25% lowlenthal serum in 150mM phosphate buffered saline buffer, 1mM EDTA, 0.05%Tween 20,0.01% thiomersal(ate), pH 7.4) to the preincubation 1.5 hours 25 ℃ of the serial dilution thing (starting from 67ng/ml) of the aliquot sample of the human serum storehouse RAST 4+ of Bet v 2 and 3+ (50 μ l) and wild-type allergen and mutant thereof.Then mixture is added in the dull and stereotyped aperture of ELISA polystyrene (polystirene) and at 25 ℃ of incubations 1.5 hours, the anti-IgE of this aperture absorption people.With phosphoric acid buffer, the 0.05%Tween-20 of 0.06M, after pH6.5 washing three times, add 0.1ml biotinylation Bet v 2 antigens (85.3ng/ml) in dilution buffer liquid and 25 ℃ of incubations 1 hour.Wash after three times, add peroxidase-Streptavidin (0.1 μ g/ml) 30 minutes at 25 ℃.With 100 μ l 1N HCl, carry out colorimetric reaction and use spectrophotometer at 450nm place reading.
Suppressing percentage ratio is calculated as follows: 100x[(A-B)/A], the absorbancy that when wherein A is unrestraint thing, 450nm place is measured, and B is the absorbancy while there is inhibition.
The scheme of embodiment 6-immunization Balb/c mouse
The emulsion subcutaneous inoculation of 200 μ l for two groups of 5 female Balb/c mouse (Charles River), this emulsion contains the 20 μ g antigens (SEQ IDNO:1, SEQ ID NO:5) in 100 μ l complete Freund's adjuvants and 100 μ l salt solution.Other three booster immunizations carry out with the interval of 1 week, and the full adjuvant that toos many or too much for use is replaced Freund's complete adjuvant.In contrast, 5 mouse are used incoherent antigen.Latter 7 days of last immunity, obtains blood sample from jugular vein, the replying with check antibody and every kind of immunogenic substance for ELISA.For the mouse of SEQ ID NO:5 immunity, also analyzed the ability of identification wild-type protein.
The IgG-specificity that embodiment 7-ELISA analyzes in immune mouse is replied
In 50mM carbonate/bicarbonate damping fluid (pH 9.6), the wild-type Bet v 2 of same amount and variant SEQ ID NO:5 (0.25 μ g) incubation at 4 ℃ is used on the hole of polystyrene board to be adsorbed onto elisa assay for 16 hours.This is the washing soln (phosphate buffered saline buffer that 60mM contains 0.05%Tween-20 for hole, pH 6.5) washing, and seal with diluting soln (25% horse serum in 150mM phosphate buffered saline buffer, 1mM EDTA, 0.05%Tween 20,0.01% thiomersal(ate), pH 7.4).The aliquot sample of the serial dilution thing (in dilution buffer liquid) of every mice serum of 100 μ l is placed in every hole, and in 25 ℃ of incubations 2 hours.
Wash after three times, the anti-mouse IgG serum of 1: 2000 dilution peroxidase conjugated in dilution buffer liquid, and join in aperture, follow 25 ℃ of incubations 1.5 hours.After washing three times, add 100 μ lTMB reagent (BioFX Laboratories, Owings Mills, MD) and within 15 minutes, carry out colorimetric reaction at 25 ℃ of incubations.By 100 μ l 1N HCl termination reactions and use spectrophotometer at 450nm place reading.Fig. 3 and 4 shows the average response obtaining by analyzing the serum of 5 mouse of every group.
Reference
1)Malling H.J.,(1998)“Immunotherapy as an effective tool in allergytreatment”.Allergy,53:461.
2)Toubi E.,Kessel A.,Blant A.,Golan T.D.,(1999)“Follow-up aftersystemic adverse reactions of immunotherapy”.Allergy,54(6):617-620.
3)Akdis C.A.,Blaser K.,(2000)“Regulation of specific immune responseby chemical and structural modifications of allergens”.Int.Arch.AllergyImmmunol.,121(4):261-269.
4)Visco V,Dolecek C,Denépoux S,Le Mao J,Guret C,Rousset F,Guinnepain MT,Kraft D,Valenta R,Weyer A,Banchereau J,Lebecque S.(1996).“Human IgG monoclonal antibodies that modulate the binding ofspecific IgE to birch pollen Bet v 1”.J.Immunol.157:956-962.
5)Vrtala S,Ball T,Spitzauer s,Pandjaitan B,Suphioglu C,Knox B,SperrWR,Valent P,Kraft D,Valenta R.(1998).“Immunization with purified naturaland recombinant allergens induces mouse IgG1 antibodies that recognizesimilar epitopes as human IgE and inhibit the human IgE-allergen interactionand allergen-induced basophil degranulation”.J Immunol 160:6137.
6)Breiteneder H.,Pettanburger K.,Bito A et al.(1989).“The gene codingfor the major birch pollen allergen Bet v 1,is highly homologous to a peadisease resistance response gene”.EMBO J,8:1935-1938.
7)Valenta R.,Duchene M.,Pettenburger K.,Sillaber C.,Valent P.,Bettelheim P.,Breitenbach M.,Rumpold H.,Kraft D.,Scheiner O.(1991).″Identification of profilin as a novel pollen allergen;IgE autoreactivity insensitized individuals.″.Science 253:557-560
8)Goldschmidt-Clermont PJ.,Kim J.,Machesky LM.,Rhee S.,PollardTD.(1991).“Regulation of phospholipase C-Y by profilin and tytosinephosphorilation”.Science,251:1231-3.
9)Carlsson I.,Nystrom LE.,Sundkvist F.,Markey F.,Lindberg U.(1977).“Actin polymerization is influenced by profilin,a low molecular weight proteinin non muscle-cells”.J Mol Biol,115:465:83.
10)Mittermann I,Swoboda I,Pierson E,Eller N,Kraft D,Valenta R,Heberle-Bors E.(1995).“Molecular cloning and characterization of profilinfrom tobacco (Nicotiana tabacum):increased profilin expression duringpollen maturation”.Plant Mol Biol.27(1):137-46.
11)Valenta R.,Duchene M.,Ebner C.,Valent P.,Sillaber C.,Deviller P.,Ferreira F.,Tejkl M.,Edelmann H.,Kraft D.,et al.(1992).“Profilins constitutea novel family of functional plant pan-allergens”J.Exp.Med,175:377-85.
12)Radauer C.,Hoffmann-Sommergruber K.(2004).“Profilin”.Plant foodallergens.IN mills ENC,sherry PR,Editors.Plant food allergen.Oxford:Blackwell Pubishing.(2004).105-24.
13)Niederberger V,Pauli G,Gronlund H,Froschl R,Rumpold H,Kraft D,Valenta R,Spitzauer S.(1998).“Recombinantbirch pollen allergens(rBet v 1and rBet v 2)contain most of the IgE epitopes present in birch,alder,hornbeam,hazel,and oak pollen:A quantitative IgE inhibition study with serafrom different populations”.J.Allergy Clin Immunol.102:579-91.
14)Mari A.,(2001).“Multiple pollen sensitization:a molecular approach tothe diagnosis”.Int Arch Allergy Immunol.125:(57-65).
15)van Ree R.,Voitenko V.,van Leeuwen WA.,Aalberse RC.(1992).“Profilin is a cross-reactive allergen in pollen and vegetabe foods”.Int ArchAllergy Immunol 98:97:104.
16)Ganglberger E.,Radauer C.,Wagner S et al.(2001).“Hev b 8,theHevea brasiliensis latex profilin,is a cross-reactive allergen of latex,plantfoods and pollen”.Int Arch Allergy Immunol.125:216-27.
17)Giehl K,Valenta R,Rothkegel M,Ronsiek M,Mannherz HG,JockuschBM.(1994)“Interaction of plant profilin with mammalian actin”.Eur JBiochem.226(2):681-9.
18)Staiger CJ,Yuan M,Valenta R,Shaw PJ,Warn RM,Lloyd CW(1994).“Microinjected profilin affects cytoplasmic streaming in plant cells by rapidlydepolymerizing actin microfilaments”.Curr Biol.Mar 1;4(3):215-9.
19)Rothkegel M,Mayboroda O,Rohde M,Wucherpfennig C,Valenta R,Jockusch BM.(1g96).“Plant and animal profilins are functionally equivalentand stabilize microfilaments in living animal cells”.J Cell Sci.109(Pt 1):83-90.
20)Almo SC,Pollard TD,Way M,Lattman EE(1994).“Purification,characterization and crystallization of Acanthamoeba profilin expressed inEscherichia coli”.J Mol Biol.236(3):950-2.
21)Fedorov AA,Pollard TD,Almo SC.(1994).“Purification,characterization and crystallization of human platelet profilin expressed inEscherichia coli”.J Mol Biol.241(3):480-2.
22)Fedorov AA,Ball T,Mahoney NM,Valenta R,Almo SC.(1997).“Themolecular basis for allergen cross-reactivity:crystal structure and IgE-epitopemapping of birch pollen profilin”.Structure.5:33-45
23)Radauer C,Willerroider M,Fuchs H,Hoffmann-Sommergruber K,Thalhamer J,Ferreira F,Scheiner O,Breiteneder H.(2006).“Cross-reactiveand species-specific immunoglobulin E epitopes of plant profilins:anexperimental and structure-based analysis”.Journal Clin Exp Allergy 2006;36(7):920-929.
24)Rossi RE.,Monasterolo G.,Operti D.,Corsi M.(1996).“Evaluation ofrecombinant allergens Bet v 1 and Bet v 2(profilin)by Pharmacia CAPsystem in patients with pollen-related allergy to birch and apple”.Allergy,51:940-5.
25)Vrtala S,Wiedemann P,Mittermann I,Eichler HG,Sperr WR,ValentP,Kraft D,Valenta F.(1996).“High-level expression in Escherichia coli andpurification of recombinant plant profilins:comparison of IgE-binding capacityand allergenic activity”.Biochem Biophys Res Commun 226(1):42-50.
26)Wiedemann P,Giehl K,Almo SC,Fedorov AA,Girvin M,SteinbergerP,Rudiger M,Ortner M,Sippl M,Dolecek C,Kraft D,Jockusch B,Valenta R.(1996).“Molecular and structural analysis of a continuous birch profilinepitope defined by a monoclonal antibody”.J Biol Chem.271(47):29915-29921.
27)Lopez-Torrejon G,Diaz-Perales A,Rodriguez J,Sanchez-Monge R,Crespo JF,Salcedo G,Pacios LF.(2007).“An experimental andmodeling-based approach to locate IgE epitopes of plant profilin allergens”.JAllergy Clin Immunol.119:1481-8.
28)Paul,(1989),“Fundamental Immunology”,Raven press,New York.
29)Cryz,S.J.(1991),“Immunotherapy and Vaccines”,VCHVerlagsgesellschaft.
30)Wang W.,Malcolm BA.(2002).“Two-stage polymerase chain reactionprotocol allowing introduction of multiple mutations,deletions,and insertions,using QuikChange site-directed mutagenesis”.Methods Mol Biol.;182:37-43.
31)Younghee Kim.(2004).“Cloning and Expression of a Lipase Genefrom Rice(Oryza sativa cv.Dongjin)”.Mol.Cells,18(1):40-45.
32)Asturias JA,lbarrola I,Eseverri JL,Arilla MC,Gonzales-Rioja R,Martinez A.(2004).“PCR-based cloning and immunological characterizationof Parietaria judaica pollen profilin”.J Investig Allergol Clin Immunol,14:43-48.
Sequence table
<110> Lofarma S. P. A. (LOFARMA S.P.A.)
The main allergenic low allergenicity variant of <120> betula pendula pollen
<130>8025MEUR
<160>12
<170>PatentIn version 3 .3
<210>1
<211>133
<212>PRT
<213> is unknown
<220>
<223> is from the wild-type Bet v 2 of betula pendula (Betula verrucosa)
<400>1
Met Ser Trp Gln Thr Tyr Val Asp Glu His Leu Met Cys Asp Ile Asp
1 5 10 15
Gly Gln Ala Ser Asn Ser Leu Ala Ser Ala Ile Val Gly His Asp Gly
20 25 30
Ser Val Trp Ala Gln Ser Ser Ser Phe Pro Gln Phe Lys Pro Gln Glu
35 40 45
Ile Thr Gly Ile Met Lys Asp Phe Glu Glu Pro Gly His Leu Ala Pro
50 55 60
Thr Gly Leu His Leu Gly Gly Ile Lys Tyr Met Val Ile Gln Gly Glu
65 70 75 80
Ala Gly Ala Val Ile Arg Gly Lys Lys Gly Ser Gly Gly Ile Thr Ile
85 90 95
Lys Lys Thr Gly Gln Ala Leu Val Phe Gly Ile Tyr Glu Glu Pro Val
100 105 110
Thr Pro Gly Gln Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu
115 120 125
Ile Asp Gln Gly Leu
130
<210>2
<211>133
<212>PRT
<213> is unknown
<220>
<223>Bet v 2 mutant
<400>2
Met Ser Trp Gln Thr Tyr Val Asp Glu His Leu Met Cys Asp Ile Asp
1 5 10 15
Gly Gln Ala Ser Asn Ser Leu Ala Ser Ala Ile Val Gly His Asp Gly
20 25 30
Ser Val Trp Ala Gln Ser Ala Ser Phe Pro Gln Phe Lys Pro Gln Glu
35 40 45
Ile Thr Gly Ile Met Lys Asp Phe Glu Glu Pro Gly His Leu Ala Pro
50 55 60
Thr Gly Leu His Leu Gly Gly Ile Lys Tyr Met Val Ile Gln Gly Glu
65 70 75 80
Ala Gly Ala Val Ile Arg Gly Lys Lys Gly Ser Gly Gly Ile Thr Ile
85 90 95
Lys Lys Thr Gly Gln Ala Leu Val Phe Gly Ile Tyr Glu Glu Pro Val
100 105 110
Thr Pro Gly Gln Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu
115 120 125
Ile Asp Gln Gly Leu
130
<210>3
<211>133
<212>PRT
<213> is unknown
<220>
<223>Bet v 2 mutant
<400>3
Met Ser Trp Gln Thr Tyr Val Asp Glu His Leu Met Cys Asp Ile Asp
1 5 10 15
Gly Gln Ala Ser Asn Ser Leu Ala Ser Ala Ile Val Gly His Asp Gly
20 25 30
Ser Val Trp Ala Gln Ser Ser Ser Phe Pro Gln Phe Thr Pro Gln Glu
35 40 45
Ile Thr Gly Ile Met Lys Asp Phe Glu Glu Pro Gly His Leu Ala Pro
50 55 60
Thr Gly Leu His Leu Gly Gly Ile Lys Tyr Met Val Ile Gln Gly Glu
65 70 75 80
Ala Gly Ala Val Ile Arg Gly Lys Lys Gly Ser Gly Gly Ile Thr Ile
85 90 95
Lys Lys Thr Gly Gln Ala Leu Val Phe Gly Ile Tyr Glu Glu Pro Val
100 105 110
Thr Pro Gly Gln Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu
115 120 125
Ile Asp Gln Gly Leu
130
<210>4
<211>133
<212>PRT
<213> is unknown
<220>
<223>Bet v 2 mutant
<400>4
Met Ser Trp Gln Thr Tyr Val Asp Glu His Leu Met Cys Asp Ile Asp
1 5 10 15
Gly Gln Ala Ser Asn Ser Leu Ala Ser Ala Ile Val Gly His Asp Gly
20 25 30
Ser Val Trp Ala Gln Ser Ser Ser Phe Pro Gln Phe Lys Pro Gln Glu
35 40 45
Ile Thr Gly Ile Met Lys Asp Phe Glu Glu Pro Gly His Leu Ala Pro
50 55 60
Thr Gly Leu His Leu Gly Gly Ile Lys Tyr Met Val Ile Gln Gly Glu
65 70 75 80
Ala Gly Ala Val Ile Arg Gly Gly Glu Gly Ser Gly Gly Ile Thr Ile
85 90 95
Lys Lys Thr Gly Gln Ala Leu Val Phe Gly Ile Tyr Glu Glu Pro Val
100 105 110
Thr Pro Gly Gln Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu
115 120 125
Ile Asp Gln Gly Leu
130
<210>5
<211>133
<212>PRT
<213> is unknown
<220>
<223>Bet v 2 mutant
<400>5
Met Ser Trp Gln Thr Tyr Val Asp Glu His Leu Met Cys Asp Ile Asp
1 5 10 15
Gly Gln Ala Ser Asn Ser Leu Ala Ser Ala Ile Val Gly His Asp Gly
20 25 30
Ser Val Trp Ala Gln Ser Lys Ser Phe Pro Gln Phe Thr Pro Gln Glu
35 40 45
Ile Thr Gly Ile Met Lys Asp Phe Glu Glu Pro Gly His Leu Ala Pro
50 55 60
Thr Gly Leu His Leu Gly Gly Ile Lys Tyr Met Val Ile Gln Gly Glu
65 70 75 80
Ala Gly Ala Val Ile Arg Gly Gly Glu Gly Ser Gly Gly Ile Thr Ile
85 90 95
Lys Lys Thr Gly Gln Ala Leu Val Phe Gly Ile Tyr Glu Glu Pro Val
100 105 110
Thr Pro Gly Gln Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu
115 120 125
Ile Asp Gln Gly Leu
130
<210>6
<211>133
<212>PRT
<213> is unknown
<220>
<223>Bet v 2 mutant
<400>6
Met Ser Trp Gln Thr Tyr Val Asp Glu His Leu Met Cys Asp Ile Asp
1 5 10 15
Gly Gln Ala Ser Asn Ser Leu Ala Ser Ala Ile Val Gly His Asp Gly
20 25 30
Ser Val Trp Ala Gln Ser Ala Ser Phe Pro Gln Phe Lys Pro Gln Glu
35 40 45
Ile Thr Gly Ile Met Lys Asp Phe Glu Glu Pro Gly His Leu Ala Pro
50 55 60
Thr Gly Leu His Leu Gly Gly Ile Lys Tyr Met Val Ile Gln Gly Glu
65 70 75 80
Ala Gly Ala Val Ile Arg Gly Gly Glu Gly Ser Gly Gly Ile Thr Ile
85 90 95
Lys Lys Thr Gly Gln Ala Leu Val Phe Gly Ile Tyr Glu Glu Pro Val
100 105 110
Thr Pro Gly Gln Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu
115 120 125
Ile Asp Gln Gly Leu
130
<210>7
<211>402
<212>DNA
<213> is unknown
<220>
<223> is from the encoding sequence of the wild-type Bet v 2 of betula pendula
<400>7
atgtcgtggc aaacgtacgt ggatgaacat ttgatgtgcg atatcgacgg gcaagccagc 60
aactcgctgg catctgcgat cgtcggtcac gatggctctg tgtgggccca gagctcttcc 120
ttcccacagt ttaagcctca ggaaatcact ggtatcatga aggactttga ggagccgggt 180
catcttgctc cgacgggctt acaccttggg ggcataaaat acatggtcat ccagggagag 240
gctggtgctg tcatccgtgg aaagaaggga tctggaggta ttactataaa gaagactggt 300
caagctctcg tttttggcat ctatgaagag cctgtgacac caggacagtg caacatggtt 360
gttgagaggt tgggggatta ccttattgac cagggcctgt ag 402
<210>8
<211>402
<212>DNA
<213> is unknown
<220>
The encoding sequence of <223>Bet v 2 mutant
<400>8
atgtcgtggc aaacgtacgt ggatgaacat ttgatgtgcg atatcgacgg gcaagccagc 60
aactcgctgg catctgcgat cgtcggtcac gatggctctg tgtgggccca gagcgcttcc 120
ttcccacagt ttaagcctca ggaaatcact ggtatcatga aggactttga ggagccgggt 180
catcttgctc cgacgggctt acaccttggg ggcataaaat acatggtcat ccagggagag 240
gctggtgctg tcatccgtgg aaagaaggga tctggaggta ttactataaa gaagactggt 300
caagctctcg tttttggcat ctatgaagag cctgtgacac caggacagtg caacatggtt 360
gttgagaggt tgggggatta ccttattgac cagggcctgt ag 402
<210>9
<211>402
<212>DNA
<213> is unknown
<220>
The encoding sequence of <223>Bet v 2 mutant
<400>9
atgtcgtggc aaacgtacgt ggatgaacat ttgatgtgcg atatcgacgg gcaagccagc 60
aactcgctgg catctgcgat cgtcggtcac gatggctctg tgtgggccca gagctcttcc 120
ttcccacagt ttacgcctca ggaaatcact ggtatcatga aggactttga ggagccgggt 180
catcttgctc cgacgggctt acaccttggg ggcataaaat acatggtcat ccagggagag 240
gctggtgctg tcatccgtgg aaagaaggga tctggaggta ttactataaa gaagactggt 300
caagctctcg tttttggcat ctatgaagag cctgtgacac caggacagtg caacatggtt 360
gttgagaggt tgggggatta ccttattgac cagggcctgt ag 402
<210>10
<211>402
<212>DNA
<213> is unknown
<220>
The encoding sequence of <223>Bet v 2 mutant
<400>10
atgtcgtggc aaacgtacgt ggatgaacat ttgatgtgcg atatcgacgg gcaagccagc 60
aactcgctgg catctgcgat cgtcggtcac gatggctctg tgtgggccca gagctcttcc 120
ttcccacagt ttaagcctca ggaaatcact ggtatcatga aggactttga ggagccgggt 180
catcttgctc cgacgggctt acaccttggg ggcataaaat acatggtcat ccagggagag 240
gctggtgctg tcatccgtgg aggggaggga tctggaggta ttactataaa gaagactggt 300
caagctctcg tttttggcat ctatgaagag cctgtgacac caggacagtg caacatggtt 360
gttgagaggt tgggggatta ccttattgac cagggcctgt ag 402
<210>11
<211>402
<212>DNA
<213> is unknown
<220>
The encoding sequence of <223>Bet v 2 mutant
<400>11
atgtcgtggc aaacgtacgt ggatgaacat ttgatgtgcg atatcgacgg gcaagccagc 60
aactcgctgg catctgcgat cgtcggtcac gatggctctg tgtgggccca gagctcttcc 120
ttcccacagt ttacgcctca ggaaatcact ggtatcatga aggactttga ggagccgggt 180
catcttgctc cgacgggctt acaccttggg ggcataaaat acatggtcat ccagggagag 240
gctggtgctg tcatccgtgg aggggaggga tctggaggta ttactataaa gaagactggt 300
caagctctcg tttttggcat ctatgaagag cctgtgacac caggacagtg caacatggtt 360
gttgagaggt tgggggatta ccttattgac cagggcctgt ag 402
<210>12
<211>402
<212>DNA
<213> is unknown
<220>
The encoding sequence of <223>Bet v 2 mutant
<400>12
atgtcgtggc aaacgtacgt ggatgaacat ttgatgtgcg atatcgacgg gcaagccagc 60
aactcgctgg catctgcgat cgtcggtcac gatggctctg tgtgggccca gagcgcttcc 120
ttcccacagt ttaagcctca ggaaatcact ggtatcatga aggactttga ggagccgggt 180
catcttgctc cgacgggctt acaccttggg ggcataaaat acatggtcat ccagggagag 240
gctggtgctg tcatccgtgg aggggaggga tctggaggta ttactataaa gaagactggt 300
caagctctcg tttttggcat ctatgaagag cctgtgacac caggacagtg caacatggtt 360
gttgagaggt tgggggatta ccttattgac cagggcctgt ag 402
Claims (11)
1. low allergenicity protein, it is the main allergenic sequence variants of Bet v2, wherein said protein:
A) with by the wild-type Bet v2 allergen shown in SEQ ID NO:1 compare, the reactivity of IgE is reduced; With
B) by least one position Ser at SEQ ID NO:1
39, Lys
45, Lys
88or Lys
89ser or the replacement of Lys residue from SEQ ID NO:1, obtain, wherein said Ser or Lys residue are substituted by the amino-acid residue that is selected from Ala, Thr, Ser, Gly, Glu and Asp.
2. according to the low allergenicity protein of claim 1, it is selected from SEQ ID NO:2-6.
3. nucleic acid molecule, its coding claim 1 or 2 protein.
4. according to the nucleic acid molecule of claim 3, it is selected from SEQ ID NO:8-12.
5. carrier, the nucleic acid molecule that it contains claim 3 or 4.
6. host cell, the carrier that it contains claim 5.
7. pharmaceutical composition, its claim that contains significant quantity 1 or 2 low allergenicity protein, and pharmaceutically acceptable carrier.
8. pharmaceutical composition, its claim that contains significant quantity 1 or 2 low allergenicity protein, and vehicle.
9. according to the composition of claim 7 or 8, it is vaccine form.
10. the purposes in the pharmaceutical composition of the preventative or therapeutic treatment of the allergic disease that claim 1 or 2 low allergenicity protein cause at the plant pollen for the preparation of by from betula pendula species.
11. according to the purposes of claim 10, and wherein said allergic disease is selected from bronchial asthma and allergic conjunctivitis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT001819A ITMI20071819A1 (en) | 2007-09-19 | 2007-09-19 | HYPOALLERGENIC VARIATIONS OF ALLERGENES GREATER BET V 2 BERRY OF BETULA VERRUCOSA |
ITMI2007A001819 | 2007-09-19 | ||
PCT/EP2008/007726 WO2009036949A1 (en) | 2007-09-19 | 2008-09-16 | Hypoallergenic variants of the major allergen from betula verrucosa pollen |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101861331A CN101861331A (en) | 2010-10-13 |
CN101861331B true CN101861331B (en) | 2014-07-16 |
Family
ID=40029196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880116680.6A Active CN101861331B (en) | 2007-09-19 | 2008-09-16 | Hypoallergenic variants of the major allergen from betula verrucosa pollen |
Country Status (11)
Country | Link |
---|---|
US (1) | US8591907B2 (en) |
EP (1) | EP2201031B1 (en) |
CN (1) | CN101861331B (en) |
AU (1) | AU2008300864B2 (en) |
CA (1) | CA2700047C (en) |
DK (1) | DK2201031T3 (en) |
EA (1) | EA019696B1 (en) |
ES (1) | ES2460573T3 (en) |
IT (1) | ITMI20071819A1 (en) |
MX (1) | MX2010002997A (en) |
WO (1) | WO2009036949A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI20115374A0 (en) * | 2011-04-18 | 2011-04-18 | Teknologian Tutkimuskeskus Vtt Oy | New hypoallergens |
RU2732013C1 (en) * | 2019-12-11 | 2020-09-10 | Федеральное бюджетное учреждение науки "Государственный научный центр прикладной микробиологии и биотехнологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ПМБ) | Method for sensibilization of plate for enzyme immunoassay by insoluble protein antigens |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007073907A1 (en) * | 2005-12-29 | 2007-07-05 | Lofarma S.P.A. | Hypoallergenic variants of the major allergen from betula verrucosa pollen |
-
2007
- 2007-09-19 IT IT001819A patent/ITMI20071819A1/en unknown
-
2008
- 2008-09-16 DK DK08802256.1T patent/DK2201031T3/en active
- 2008-09-16 MX MX2010002997A patent/MX2010002997A/en not_active Application Discontinuation
- 2008-09-16 CN CN200880116680.6A patent/CN101861331B/en active Active
- 2008-09-16 CA CA2700047A patent/CA2700047C/en active Active
- 2008-09-16 EA EA201000360A patent/EA019696B1/en not_active IP Right Cessation
- 2008-09-16 AU AU2008300864A patent/AU2008300864B2/en active Active
- 2008-09-16 EP EP08802256.1A patent/EP2201031B1/en active Active
- 2008-09-16 ES ES08802256.1T patent/ES2460573T3/en active Active
- 2008-09-16 WO PCT/EP2008/007726 patent/WO2009036949A1/en active Application Filing
- 2008-09-16 US US12/679,207 patent/US8591907B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007073907A1 (en) * | 2005-12-29 | 2007-07-05 | Lofarma S.P.A. | Hypoallergenic variants of the major allergen from betula verrucosa pollen |
Non-Patent Citations (1)
Title |
---|
Susanne Vrtala et al.High-Level Expression in Escherichia cloi and Purification of Recombinant Plant Profilins:comparison of IgE-Binding Capacity and Allergenic Activity.《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》.1996,第226卷(第1039期),第42-50页. * |
Also Published As
Publication number | Publication date |
---|---|
EP2201031A1 (en) | 2010-06-30 |
DK2201031T3 (en) | 2014-05-05 |
EA201000360A1 (en) | 2010-10-29 |
ES2460573T3 (en) | 2014-05-13 |
CA2700047A1 (en) | 2009-03-26 |
WO2009036949A1 (en) | 2009-03-26 |
EA019696B1 (en) | 2014-05-30 |
US8591907B2 (en) | 2013-11-26 |
AU2008300864B2 (en) | 2014-02-27 |
US20100310590A1 (en) | 2010-12-09 |
ITMI20071819A1 (en) | 2009-03-20 |
MX2010002997A (en) | 2010-06-01 |
CN101861331A (en) | 2010-10-13 |
CA2700047C (en) | 2017-01-17 |
EP2201031B1 (en) | 2014-03-19 |
AU2008300864A1 (en) | 2009-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014276484B2 (en) | Contiguous overlapping peptides for treatment of house dust mites allergy | |
Asturias et al. | Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen‐specific immunotherapy | |
CN103649315B (en) | Low-allergen | |
AU2006331005B2 (en) | Hypoallergenic variants of the major allergen from Betula verrucosa pollen | |
CN101861331B (en) | Hypoallergenic variants of the major allergen from betula verrucosa pollen | |
Marazuela et al. | A non-allergenic Ole e 1-like protein from birch pollen as a tool to design hypoallergenic vaccine candidates | |
Bonura et al. | A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination | |
Cromwell et al. | Clinical experience with recombinant molecules for allergy vaccination | |
EP2393511A2 (en) | Contiguous overlapping peptides for treatment of birch pollen allergy | |
Marazuela et al. | Hypoallergenic mutants of Ole e 1, the major olive pollen allergen, as candidates for allergy vaccines | |
CA2843804C (en) | Hypoallergenic variants of mal d 1, the major allergen from malus domestica | |
Zhao et al. | Generation of a chimeric dust mite hypoallergen using DNA shuffling for application in allergen-specific immunotherapy | |
Qin et al. | Construction by artificial intelligence and immunovalidation of hypoallergenic mite allergen Der f 36 vaccine | |
EP2281836B1 (en) | Hybrid proteins from Parietaria judaica major allergens and uses thereof | |
Bonura et al. | Genetic engineering of allergens for immunotherapy | |
ITMI20112301A1 (en) | HYPOALLERGENIC VARIATIONS OF THE ALLERGEN HIGHER PHL P 5 OF PHLEUM PRATENSE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |